

BIOISOSTERIC APPROACH TO INVESTIGATION OF LIGAND BINDING MODE AT 5-HT₆R



Jakub Staroń¹, Dawid Warszycki¹, Justyna Kalinowska-Tłuścik², Andrzej J. Bojarski¹

¹Department of Medicinal Chemistry, Institute of Pharmacology PAS, Smętna 12, 31-343 Kraków, Poland

²Department of Crystal Chemistry and Crystal Physics, Jagiellonian University Faculty of Chemistry R. Ingardena 3, 30-060 Kraków, Poland



Introduction

5-HT₆ receptor was recognized as promising target, among other, for novel antidepressant and pro-cognitive drugs.

Up to date, several thousands of chemical compounds acting at this target were acquired. Almost all of them contain basic nitrogen atom and about 85% of them contain sulphonyl group as a pharmacophore feature. These moieties were commonly recognized as essential for ligand-5-HT₆R interactions.¹⁻⁴ However, the discovery of highly active ligands without sulphonyl moiety, together with the discovery of non-basic ligands, made current knowledge necessary to be updated. Several scientific groups tried to provide explanation for activity of novel ligands, but there is still much to be discovered.^{5,6}

Crystal structures

Crystal structures of 14 compounds (**1**, **2**, **6**, **7**, **8**, **10**, **11**, **12**, **13**, **14**, **16**, **18**, **19**, **21** - table 1) were obtained. All of them were next described by four geometrical parameters (table 2).

Geometrical parameters compound 6 as an example

Angle 1 - a plane angle defined by two aromatic systems

Angle 2 - a torsion angle defined by atoms At1-At2-At3-At4

Distances between centroids of aromatic rings (dist. 1) and between basic nitrogen atom and peripheral aromatic ring (dist. 2).





Table 2. Geometrical parameters of crystallized compounds.

Compd. No.	K _i [nM]	angle 1 [°]	angle 2 [°]	dist. 1 [Å]	dist. 2 [Å]
1	1	83.14	93.82	5.322	9.138
2	1280	54.00	135.41	6.452	9.785
6	11	84.28	106.98	5.448	8.146
7	44	53.62	45.43	6.540	7.344
8	23	74.46	67.85	6.010	7.829
10	21	89.92	136.80	5.059	6.771
11	245	21.43	165.32	6.209	10.004
12	62	22.61	163.76	6.428	9.956
13	6	59.21	62.01	5.523	7.335
14	4	89.17	104.28	5.224	9.054
16	18	83.10	35.81	5.889	8.663
16^a	18	82.27	146.29	5.163	9.604
18	2204	55.29	139.72	6.487	10.676
18^b	2204	56.06	136.91	6.496	10.775
19^a	2204	72.56	136.04	6.485	10.845
19^b	2204	67.93	122.08	6.474	10.565
19	24	86.76	158.78	5.412	10.569
21	63	79.38	108.39	6.633	8.527

^a crystal structure of **16** contains two compound molecules in the asymmetric unit.

^b crystal structure of **18** contains four compound molecules in the asymmetric unit.

Average geometrical parameters for most active compounds (K_i < 30 nM) are equal: angle 1 = 81.37 ± 9.11°, angle 2 = 101.40 ± 38.93°, dist. 1 = 5.450 ± 0.241 Å, dist. 2 = 8.534 ± 1.038 Å.



SIFT representation

For each compound, only the best docking pose per receptor model was considered and 100 the best scored complexes were transformed into bitstring applying SIFT formalism statistically describing interactions between ligand and receptor.^{7,8}

Residue	[%] compounds interacting with residue		average SIFT	
	active	inactive	active	inactive
	K _i < 100 nM	K _i > 100 nM	K _i < 100 nM	K _i > 100 nM
W3.28	42	50	0.69	0.72
T3.29	83	75	0.68	0.62
D3.32	100	83	0.88	0.78
V3.33	100	100	0.90	0.83
C3.36	100	83	0.81	0.76
L4.61	50	50	0.62	0.61
G146	0	25	-	0.60
R162	0	17	-	0.57
L163	100	92	0.98	0.92
L164	67	67	0.71	0.76
A165	100	92	0.82	0.74
F5.38	100	100	0.81	0.76
V5.39	100	100	0.85	0.83
A5.42	92	83	0.72	0.70
S5.43	33	50	0.82	0.64
T5.46	75	42	0.61	0.65
W6.48	75	50	0.64	0.57
F6.51	100	100	0.99	0.95
F6.52	100	83	0.79	0.73
N6.55	100	92	0.85	0.82
V6.58	58	17	0.66	0.71
F7.35	100	100	0.99	0.99
D7.36	17	50	0.62	0.72
T7.39	100	100	0.92	0.84
Y7.43	100	83	0.73	0.70

Acknowledgements

This research was supported by the following projects: Interdisciplinary PhD Studies "Molecular sciences for medicine" (co-financed by the European Social Fund within the Human Capital Operational Programme) and UDA-POIG.01.03.01-12-063/09-00 "Antagonists of 5-HT₆ receptor as advanced antipsychotics with pro-cognitive properties" co-financed by European Union from the European Fund of Regional Development (EFRD). The crystallographic research was carried out with equipment purchased using financial support of the European Regional Development Fund in the framework of the Polish Innovative Economy Operational Program (contract no. POIG.02.01.00-12-023/08).

Compounds design

The basis for compound design was provided by bioisostere database generated in Open Eye Pipeline-Pilot programme generated on 5-HT₆R ligands stored in ChEMBL. Three methods of ligand design were implemented;

- virtual screening protocol of bioisostere database,
- comparison of bioisostere database with commercially available compounds,
- comparison of bioisostere database with database of D2R ligands (taken from ChEMBL).

All three methods provided finally 22 compounds representing eight bioisosteric substitutions (table 1).


Bioisosteric pairs

Table 1. Affinity values (K_i) for 5-HT₆R in [nM] measured in our laboratory.

Ligand	Bioisostere	Type of substitution
1 (K _i = 1)	2 (K _i = 1280)	sulphonyl - carbonyl
3 (K _i = 1)	4 (K _i = 2067)	sulphonyl - carbonyl, methanediyl
5 (K _i = 116)	6 (K _i = 11)	sulphonyl - carbonyl, methanediyl
7 (K _i = 44)	8 (K _i = 23)	sulphonyl - carbonyl, methanediyl
9 (K _i = 202)	10 (K _i = 21)	noncyclic - cyclic ring expanding
11 (K _i = 245)	12 (K _i = 62)	sulphonyl - carbonyl, methanediyl
13 (K _i = 6)	14 (K _i = 4)	sulphonyl - carbonyl, methanediyl
15 (K _i = 187)	16 (K _i = 18)	sulphonyl - carbonyl, methanediyl
17 (K _i = 1)	18 (K _i = 2204)	sulphonyl - carbonyl, methanediyl
19 (K _i = 24)	20 (K _i = 22)	cyclic - noncyclic
21 (K _i = 63)	22 (K _i = 2280)	phenyl - cyclohexane piperidine - phenyl
23 (K _i = 2675)	24 (K _i = 3760)	

Virtual complexes

Docking studies revealed two possible positions of a ligand in the binding pocket. The „classical” position with basic nitrogen atom heading towards the bottom of the binding pocket (**C**) and „alternative” position with basic nitrogen atom pointing towards the entrance to the binding pocket (**D**). Different complexes of compound **3** are shown.



- References
- (1) Holenz, J. et al. Medicinal Chemistry Driven Approaches toward Novel and Selective Serotonin 5-HT₆ Receptor Ligands. J. Med. Chem. 2005, 48 (6), 1781-1795.
 - (2) Lopez-Rodriguez, M. L. et al. A Three-Dimensional Pharmacophore Model for 5-Hydroxytryptamine6 (5-HT₆) Receptor Antagonists. J. Med. Chem. 2005, 48, 4216-4219.
 - (3) Kim, H.-J. et al. New Serotonin 5-HT₆ Ligands from Common Feature Pharmacophore Hypotheses. J. Chem. Inf. Mod. 2008, 48 (1), 197-206.
 - (4) Liu, K. G. et al. Identification of a Novel Series of 3-Piperidinyl-5-Sulfonylindazoles as Potent 5-HT₆ Ligands. Bioorgan. Med. Chem. Lett. 2009, 19 (12), 3214-3216.
 - (5) Ivachtchenko, A. V. et al. Synthesis of Cycloalkane-Annelated 3-Phenylsulphonyl-pyrazolo[1,5-A]pyrimidines and Their Evaluation as 5-HT₆ Receptor Antagonists. Bioorgan. Med. Chem. Lett. 2010, 20 (7), 2133-2136.
 - (6) Harris, R. N. et al. Highly Potent, Non-Basic 5-HT₆ Ligands. Site Mutagenesis Evidence for a Second Binding Mode at 5-HT₆ for Antagonism. Bioorgan. Med. Chem. Lett. 2010, 20 (11), 3436-3440.
 - (7) Mordalski, S. et al. Protein Binding Site Analysis by Means of Structural Interaction Fingerprint Patterns. Bioorgan. Med. Chem. Lett. 2011, 21 (22), 6816-6819.
 - (8) Witek, J. et al. An Application of Machine Learning Methods to Structural Interaction Fingerprints-a Case Study of Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2013, 24 (2), 580-585.